MedTrace Logo

A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

NCT05117476 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 440

Last updated 2025-11-24

No results posted yet for this study

Summary

CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor
  • NSCLC

Interventions

DRUG

CLN-619

Anti-MICA/MICB monoclonal antibody

DRUG

Pembrolizumab

Keytruda

DRUG

Paclitaxel

Taxane

DRUG

Carboplatin AUC 6

Platinum compound

DRUG

pemetrexed

antifolate

DRUG

Datopotamab deruxtecan-dlnk (Dato-DXd)

TROP-2 antibody-drug conjugate (ADC)

Sponsors & Collaborators

  • Cullinan Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-29
Primary Completion
2026-03-31
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05117476 on ClinicalTrials.gov